P-278 A phase II study of cetuximab in combination with irinotecan plus S-1 as first-line treatment in patients with KRAS wild-type metastatic colorectal cancer (CIRIS study): overall survival analysis

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2015-06, Vol.26, p.iv82
Hauptverfasser:	Eto, T., Masuishi, T., Matsui, T., Anzai, S., Suzuki, Y., Fukami, Y., Suzuki, K., Kusano, F., Sakai, Y., Tazawa, J.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page	iv82
container_title	Annals of oncology
container_volume	26
creator	Eto, T. Masuishi, T. Matsui, T. Anzai, S. Suzuki, Y. Fukami, Y. Suzuki, K. Kusano, F. Sakai, Y. Tazawa, J.
description
doi_str_mv	10.1093/annonc/mdv233.275
format	Article
fullrecord	<record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdv233_275</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1093_annonc_mdv233_275</sourcerecordid><originalsourceid>FETCH-LOGICAL-c855-a1d7a3d90125c79e6f5f389c6bc7b9d3fc601a009eccea373df18f057d3596b73</originalsourceid><addsrcrecordid>eNotkLtOwzAUhjOAxPUB2M4IQ1o7JnHNVlVcIiqBWvboxLGFkeNEtlvoI_JWuArT-Yf_cvRl2Q0lM0oEm6Nzg5PzvtsXjM0KXp5k50QULOcluz_LLkL4IoRUohDn2e97XvAFLGH8xKCgriHEXXeAQYNUcfdjemzBOJBD3xqH0QwOvk38BOONG6KS6GC0uwDbnAIG0MaHmFvjFESvMPbKxWN-TNEkwxR-3Sy3Sdkuj4dRQa8ihpgcMu3YwSsZ0UKqlsrD7are1NvprbsHGPbKo7UQdn5v9smGDu0hmHCVnWq0QV3_38vs4-nxY_WSr9-e69VynctFWeZIO46sE4QWpeRCVbrUbCFk1Ureio5pWRGKhAglpULGWafpQpOSd6wUVcvZZUanWumHELzSzegTJH9oKGmO-JsJfzPhbxJ-9gdblIFU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>P-278 A phase II study of cetuximab in combination with irinotecan plus S-1 as first-line treatment in patients with KRAS wild-type metastatic colorectal cancer (CIRIS study): overall survival analysis</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Eto, T. ; Masuishi, T. ; Matsui, T. ; Anzai, S. ; Suzuki, Y. ; Fukami, Y. ; Suzuki, K. ; Kusano, F. ; Sakai, Y. ; Tazawa, J.</creator><creatorcontrib>Eto, T. ; Masuishi, T. ; Matsui, T. ; Anzai, S. ; Suzuki, Y. ; Fukami, Y. ; Suzuki, K. ; Kusano, F. ; Sakai, Y. ; Tazawa, J.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>DOI: 10.1093/annonc/mdv233.275</identifier><language>eng</language><ispartof>Annals of oncology, 2015-06, Vol.26, p.iv82</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Eto, T.</creatorcontrib><creatorcontrib>Masuishi, T.</creatorcontrib><creatorcontrib>Matsui, T.</creatorcontrib><creatorcontrib>Anzai, S.</creatorcontrib><creatorcontrib>Suzuki, Y.</creatorcontrib><creatorcontrib>Fukami, Y.</creatorcontrib><creatorcontrib>Suzuki, K.</creatorcontrib><creatorcontrib>Kusano, F.</creatorcontrib><creatorcontrib>Sakai, Y.</creatorcontrib><creatorcontrib>Tazawa, J.</creatorcontrib><title>P-278 A phase II study of cetuximab in combination with irinotecan plus S-1 as first-line treatment in patients with KRAS wild-type metastatic colorectal cancer (CIRIS study): overall survival analysis</title><title>Annals of oncology</title><issn>0923-7534</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNotkLtOwzAUhjOAxPUB2M4IQ1o7JnHNVlVcIiqBWvboxLGFkeNEtlvoI_JWuArT-Yf_cvRl2Q0lM0oEm6Nzg5PzvtsXjM0KXp5k50QULOcluz_LLkL4IoRUohDn2e97XvAFLGH8xKCgriHEXXeAQYNUcfdjemzBOJBD3xqH0QwOvk38BOONG6KS6GC0uwDbnAIG0MaHmFvjFESvMPbKxWN-TNEkwxR-3Sy3Sdkuj4dRQa8ihpgcMu3YwSsZ0UKqlsrD7are1NvprbsHGPbKo7UQdn5v9smGDu0hmHCVnWq0QV3_38vs4-nxY_WSr9-e69VynctFWeZIO46sE4QWpeRCVbrUbCFk1Ureio5pWRGKhAglpULGWafpQpOSd6wUVcvZZUanWumHELzSzegTJH9oKGmO-JsJfzPhbxJ-9gdblIFU</recordid><startdate>201506</startdate><enddate>201506</enddate><creator>Eto, T.</creator><creator>Masuishi, T.</creator><creator>Matsui, T.</creator><creator>Anzai, S.</creator><creator>Suzuki, Y.</creator><creator>Fukami, Y.</creator><creator>Suzuki, K.</creator><creator>Kusano, F.</creator><creator>Sakai, Y.</creator><creator>Tazawa, J.</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201506</creationdate><title>P-278 A phase II study of cetuximab in combination with irinotecan plus S-1 as first-line treatment in patients with KRAS wild-type metastatic colorectal cancer (CIRIS study): overall survival analysis</title><author>Eto, T. ; Masuishi, T. ; Matsui, T. ; Anzai, S. ; Suzuki, Y. ; Fukami, Y. ; Suzuki, K. ; Kusano, F. ; Sakai, Y. ; Tazawa, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c855-a1d7a3d90125c79e6f5f389c6bc7b9d3fc601a009eccea373df18f057d3596b73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Eto, T.</creatorcontrib><creatorcontrib>Masuishi, T.</creatorcontrib><creatorcontrib>Matsui, T.</creatorcontrib><creatorcontrib>Anzai, S.</creatorcontrib><creatorcontrib>Suzuki, Y.</creatorcontrib><creatorcontrib>Fukami, Y.</creatorcontrib><creatorcontrib>Suzuki, K.</creatorcontrib><creatorcontrib>Kusano, F.</creatorcontrib><creatorcontrib>Sakai, Y.</creatorcontrib><creatorcontrib>Tazawa, J.</creatorcontrib><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Eto, T.</au><au>Masuishi, T.</au><au>Matsui, T.</au><au>Anzai, S.</au><au>Suzuki, Y.</au><au>Fukami, Y.</au><au>Suzuki, K.</au><au>Kusano, F.</au><au>Sakai, Y.</au><au>Tazawa, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>P-278 A phase II study of cetuximab in combination with irinotecan plus S-1 as first-line treatment in patients with KRAS wild-type metastatic colorectal cancer (CIRIS study): overall survival analysis</atitle><jtitle>Annals of oncology</jtitle><date>2015-06</date><risdate>2015</risdate><volume>26</volume><spage>iv82</spage><pages>iv82-</pages><issn>0923-7534</issn><doi>10.1093/annonc/mdv233.275</doi><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 0923-7534
ispartof	Annals of oncology, 2015-06, Vol.26, p.iv82
issn	0923-7534
language	eng
recordid	cdi_crossref_primary_10_1093_annonc_mdv233_275
source	Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
title	P-278 A phase II study of cetuximab in combination with irinotecan plus S-1 as first-line treatment in patients with KRAS wild-type metastatic colorectal cancer (CIRIS study): overall survival analysis
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T06%3A47%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=P-278%20A%20phase%20II%20study%20of%20cetuximab%20in%20combination%20with%20irinotecan%20plus%20S-1%20as%20first-line%20treatment%20in%20patients%20with%20KRAS%20wild-type%20metastatic%20colorectal%20cancer%20(CIRIS%20study):%20overall%20survival%20analysis&rft.jtitle=Annals%20of%20oncology&rft.au=Eto,%20T.&rft.date=2015-06&rft.volume=26&rft.spage=iv82&rft.pages=iv82-&rft.issn=0923-7534&rft_id=info:doi/10.1093/annonc/mdv233.275&rft_dat=%3Ccrossref%3E10_1093_annonc_mdv233_275%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true